GILD vs INCY
Gilead Sciences (GILD) and Incyte (INCY) compared side by side. Gilead Sciences (GILD) is larger, with a market cap of $193.5B versus $23.5B for Incyte, about 8.2 times the size. GILD returned +32.4% over the past year including dividends, versus +29.6% for INCY, through October 23, 2026..
Head to head
| Metric | GILD | INCY |
|---|---|---|
| Market cap | $193.5B | $23.5B |
| P/E (TTM) | — | 14.7x |
| Forward P/E | 15.6x | 13.4x |
| Revenue (TTM) | $30.5B | $5.8B |
| Revenue growth | 10.2% | 37.7% |
| Gross margin | 79.6% | 55.7% |
| Operating margin | 33.7% | 41.9% |
| Free cash flow | $12.9B | $1.9B |
| Dividend yield | 2.10% | None |
| 1-year return | +32.4% | +29.6% |
| 5-year return (annual) | +22.6% | +12.0% |
| Max drawdown | -71% | -99% |
| FI Handbook grade | B- | B |
Highlighted: the stronger figure on metrics where higher or lower is clearly better.
Growth of $10,000 (5 years, price only)
$10.0K
$15.0K
$20.0K
20222023202420252026
GILD vs INCY FAQ
Which is bigger, GILD or INCY?
Gilead Sciences (GILD) is larger, with a market cap of $193.5B versus $23.5B for Incyte, about 8.2 times the size.
Which stock performed better over the past year, GILD or INCY?
GILD returned +32.4% over the past year including dividends, versus +29.6% for INCY, through October 23, 2026.
Which pays a higher dividend, GILD or INCY?
GILD yields 2.10%; INCY does not pay a dividend.
Full pages: Gilead Sciences · Incyte